![Table 1 from Evaluation of IgG, IgA and IgM monoclonal and biclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios – Hevylite assay versus immunofixation | Semantic Scholar Table 1 from Evaluation of IgG, IgA and IgM monoclonal and biclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios – Hevylite assay versus immunofixation | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c49afcb4d96fc6d5c2d81291e9e5037152a14565/7-Figure1-1.png)
Table 1 from Evaluation of IgG, IgA and IgM monoclonal and biclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios – Hevylite assay versus immunofixation | Semantic Scholar
![Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-36395-z/MediaObjects/41598_2018_36395_Fig1_HTML.png)
Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies | Scientific Reports
![a) Point-of-care test (Simtomax Õ ). CT: control line; line A: IgA/IgG... | Download Scientific Diagram a) Point-of-care test (Simtomax Õ ). CT: control line; line A: IgA/IgG... | Download Scientific Diagram](https://www.researchgate.net/publication/323299597/figure/fig1/AS:596307454472192@1519182184518/a-Point-of-care-test-Simtomax-O-CT-control-line-line-A-IgA-IgG-deamidated.png)